Evidence map›Paper›PMID 37895294›Full record

ArticleGenes2023

Malcolm Forbes, Mal Hopwood, Chad A Bousman

Open access · goldAbstract read
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Malcolm ForbesThe Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Barwon Health, Deakin University, Geelong, VIC 3220, Australia.ORCID 0000-0002-8339-6471
Mal HopwoodDepartment of Psychiatry, University of Melbourne, Parkville, VIC 3050, Australia.ORCID 0000-0001-6004-4521
Chad A BousmanDepartment of Psychiatry, University of Melbourne, Parkville, VIC 3050, Australia.ORCID 0000-0001-6303-8696
The University of Melbourne · AUBarwon Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenomic (PGx) testing to inform antidepressant medication selection and dosing is gaining attention from healthcare professionals, patients, and payors in Australia. However, there is often uncertainty regarding which test is most suitable for a particular patient. Here, we identified and evaluated the coverage of

Indexed as

Cytochrome P-450 CYP2D6Pharmacogenomic TestingAntidepressive AgentsCytochrome P-450 CYP2C19HumansVictoriaAntidepressive AgentsCYP2C19 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6CYP2C19CYP2D6personalized medicinepharmacogeneticspsychiatry

Identifiers

PMID37895294
PMCPMC10606650
OpenAlexW4387668743

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.